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ABSTRACT
Introduction Healthcare-associated pneumonia
(HCAP) is actually considered a subgroup of
hospital-acquired pneumonia due to the reported
high risk of multidrug-resistant pathogens in the
USA. Therefore, current American Thoracic Society/
Infectious Diseases Society of America guidelines
suggest a nosocomial antibiotic treatment for HCAP.
Unfortunately, the scientific evidence supporting this
is contradictory.
Methods We conducted a prospective multicentre
case–control study in Spain, comparing clinical
presentation, outcomes and microbial aetiology of
HCAP and community-acquired pneumonia (CAP)
patients matched by age (±10 years), gender and
period of admission (±10 weeks).
Results 476 patients (238 cases, 238 controls)
were recruited for 2 years from June 2008. HCAP
cases showed significantly more comorbidities
(including dysphagia), higher frequency of previous
antibiotic use in the preceding month, higher
pneumonia severity score and worse clinical status
(Charslon and Barthel scores). While microbial
aetiology did not differ between the two groups
(HCAP and CAP: Streptococcus pneumoniae: 51% vs
55%; viruses: 22% vs 12%; Legionella: 4% vs 9%;
Gram-negative bacilli: 5% vs 4%; Pseudomonas
aeruginosa: 4% vs 1%), HCAP patients showed
worse mortality rates (1-month: HCAP, 12%; CAP
5%; 1-year: HCAP, 24%; CAP, 9%), length of
hospital stay (9 vs 7 days), 1-month treatment failure
(5.5% vs 1.5%) and readmission rate (18% vs 11%)
(p<0.05, each).
Conclusions Despite a similar clinical presentation,
HCAP was more severe due to patients’ conditions
(comorbidities) and showed worse clinical outcomes.
Microbial aetiology of HCAP did not differ from CAP
indicating that it is not related to increased mortality
and in Spain most HCAP patients do not need
nosocomial antibiotic coverage.
INTRODUCTION
The current American Thoracic Society/Infectious
Diseases Society of America (ATS/IDSA) guidelines
for nosocomial pneumonia (2005) describe a new
clinical entity, healthcare-associated pneumonia
(HCAP), which includes a number of heteroge-
neous conditions possibly associated with a high
risk of multidrug-resistant (MDR) infections and
mortality.1
This new clinical entity (HCAP) indirectly
reflects substantial progress in healthcare (day hos-
pital, outpatient clinics, etc), and profound demo-
graphic (life expectancy) and sociocultural changes
in the general population.2–4 Indeed, the amount
of long-term care facility patients has rapidly
increased in recent years, pneumonia being one of
the most frequent causes of hospitalisation and
mortality.2–4 Different studies have shown that the
incidence, clinical presentation and mortality for
pneumonia in HCAP patients are similar to
hospital-acquired pneumonia.1–5–7 Similar out-
comes have been described for patients fulfilling
other HCAP criteria such as patients receiving
haemodialysis, previous antibiotic therapy, or
immunocompromised patients.5–11 Unfortunately,
there is no general consensus about the microbial
aetiology of HCAP and its influence on outcomes.
Whereas in the USA and Asia a high prevalence of
MDR pneumonia (ie, Gram-negative bacilli or
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Key messages
What is the key question?
▸ This multicentre case–control study investigates
the microbial aetiology of HCAP showing that
MDR infections are infrequent in Europe and
that a nosocomial antibiotic coverage is not
justified in these patients.
What is the bottom line?
▸ The poor outcomes observed in HCAP are
clearly a consequence of the patients’ poor
clinical condition (comorbidities).
Why read on?
▸ There results possibly indicate the need for a
closer medical follow-up rather than the use of
broad-spectrum antibiotics.
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Staphylococcus aureus) has been described, in Europe the
HCAP concept is progressively weakening due to limited evi-
dence of ‘nosocomial pathogens’.12–22
Significant differences in local healthcare organisation and in
population composition could be used to explain such microbio-
logical disparities.
Finally, the two major concerns about HCAP are: (1) the
excessive heterogeneity of HCAP definition (ie, immunosup-
pressed patients); and (2) the inadequacy of HCAP definition to
predict the risk of MDR infections.23 24
For these reasons we performed a prospective case–control
investigation on the microbial aetiology of HCAP in order to
confirm the reliability of the HCAP concept in Europe and the
role of its microbial aetiology in determining clinical outcomes.
MATERIALS AND METHODS
Study subjects
All consecutive immunocompetent adult patients hospitalised in
the 12 collaborating Spanish hospitals with a suspicion of pneu-
monia were considered for recruitment between June 2008 and
June 2010.
Two groups of patients were studied:
1. Patients with HCAP according to ATS/IDSA criteria.1 HCAP
criteria for inclusion were slightly modified in order to focus
the investigation on the risk of MDR pathogens in this
population: the time of ‘previous hospitalisation’ was
restricted to the last 2 months (instead of three); the follow-
ing criteria were added: permanent nasogastric tube; gastros-
tomy; permanent catheters; permanent urinary catheter.
2. Selected ‘control’ community-acquired pneumonia (CAP)
patients. Matching criteria were: age (±10 years), gender,
and the hospitalisation period (±10 weeks) in order to
respect patients’ demographics and seasonal variations in
microbial aetiology of pneumonia (flu, etc).
Exclusion criteria were: all causes of immunosuppression
(HIV, neoplasia, etc, excluding steroids), no written consent for
study recruitment.
Witnessed bronchoaspiration pneumonia (the inhalation of
oropharyngeal or gastric contents into the lower respiratory
tract) was not considered for the study because chemical pneu-
monitis could not be ruled out.
Data collection
Data were collected on age, gender, smoking and alcohol habits
(80 g/day, corresponding to approximately 1 l of wine, eight
standard-sized beers, or one-half pint of hard liquor each day),
previous influenza and pneumococcal vaccinations, chronic
comorbidities (cardiovascular, hepatic, renal, rheumatological,
dementia and neurological diseases, diabetes mellitus, neoplasia
in remission, etc), modified Charlson index and Barthel scale
(see tables E1 andE2 in supplementary data, available online
only) to assess comorbidities and physical activity, respectively,
chronic therapy (inhaled and systemic corticosteroids, gastropro-
tective drugs and statins), previous pneumonia, previous anti-
biotic therapy in the last month and aspiration evidence
(dysphagia scale, see table E3 in supplementary data, available
online only).
Main clinical signs and symptoms (cough, expectoration, etc)
were recorded at admission, as well as analytical data (leucocyte
count, C- reactive protein, etc), pneumonia severity index (PSI)
and CURB-65 scores (confusion, blood urea, respiratory rate,
blood pressure, age >65 years), radiological data (multilobar
infiltration, etc), antimicrobial treatment (with reference to
Spanish CAP guidelines) and use of systemic corticosteroids.25–27
Pulmonary (pleural effusion, empyema, atelectasis, cavita-
tions, respiratory distress, pneumothorax and surgical pleural
draining) and extrapulmonary complications of pneumonia
(septic shock, acute renal failure, endocarditis, meningitis,
cardiac arrhythmias, diarrhoea, myocardial infarction, cardiac
arrest, pancreatitis) were also recorded, as well as 30-day,
90-day and 1-year mortality rate (and cause of death), hospital
length of stay (LOS), clinical stability, intensive care unit (ICU)
admission and ventilatory support (invasive or non-invasive
mechanical ventilation, MV) requirement, treatment failure and
30-day and 1-year hospital readmissions.28
Patient follow-up
Surviving patients underwent a radiological and serological
follow-up at 4–6 weeks. Serial phone calls were performed
every 3 months up to 1 year after admission in order to assess
eventual readmissions, new antibiotic treatments, pneumonia
complications or fatality cases and their causes.
Microbiological investigations
Routine sampling to determine the microbial aetiology of pneu-
monia included sputum, urine for Streptococcus pneumoniae
and Legionella pneumophila antigens, blood cultures, nasopha-
ryngeal swabs for respiratory viruses and for methicillin-resistant
S aureus (MRSA). Pleural puncture, tracheobronchial aspirates
(TBAS) and bronchoalveolar lavage, when available, were col-
lected for Gram and Ziehl–Nielsen stains and for cultures for
bacterial, fungal and mycobacterial pathogens. We only consid-
ered valid sputum samples according to current microbiological
standards.29 Positive swabs for MRSA were not considered indi-
cative of MRSA-induced pneumonia if this potential aetiology
was not confirmed by a positive culture of any other respiratory
sample (sputum, TBAS, etc). Serology tests for atypical patho-
gens were performed at admission and after 4–6 weeks (see sup-
plementary data, available online only).
In case of failure to respond, a new microbiological investiga-
tion was conducted for bacterial, fungal and mycobacterial
pathogens.
Sample processing
Sample processing techniques have been described previously.30
The following respiratory viruses were studied through a reverse
transcriptase PCR technique (CLART-PneumoVir, Genomica;
see supplementary data, available online only): adenovirus;
bocavirus; coronavirus; enterovirus (echovirus); influenza virus A
(subtypes H3N2 human, H1N1 human, B, C and H1N1/2009);
metapneumovirus (subtypes A and B); parainfluenza virus 1, 2,
3, and 4 (subtypes A and B); rhinovirus; respiratory syncytial
virus type A (VSR-A) and B (VSR-B).
Statistical analysis
A descriptive analysis of all variables was performed, analysing
qualitative variables by means of absolute and relative frequen-
cies, while quantitative variables have been represented by
means, SD and CI if normally distributed, or through medians,
minimal and maximal values and IQR if they did not follow a
Gaussian distribution.
Student’s t test (parametric) and the Mann–Whitney (non-
parametric) test were used to assess significant differences in
quantitative variables. For qualitative variables, Pearson’s χ2 test,
or Fisher exact test for tables (2×2) and tests of likelihood
ratios for tables (m×n) were used.31 Student’s t and Wilcoxon
tests were used for associations of paired data in quantitative
variables. For qualitative variables McNemar tests for tables
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(2×2), or signs tests for tables (m×n) were used. A multivariate
logistic regression analysis was performed to identify factors
associated with short-term and long-term mortality. First, uni-
variate relationships were analysed, in order to identify the pos-
sible factors associated with the event (death). Second, different
models were developed with significant variables. Several sets of
significant variables were introduced into the model as it was
not possible to use them all at once, given the large sample size,
and no confounder variables were found. After adjusting several
models, one of the models with best adjustment was chosen.
95% CI for estimates and SPSS V.17.0 statistical pack were used.
RESULTS
Patients’ characteristics
We recruited 476 patients (238 HCAP cases and 238 CAP con-
trols). The main HCAP patients fulfilled one HCAP criterion
(n=207, 87%) while 9.7% (n=23) met two criteria, 3% (n=8)
three or more criteria.
The most frequent inclusion criterion was residency in long-
term care facilities (n=119; 50%), followed by recent hospital-
isation (n=100; 42%), domiciliary wound care (n=22; 9.2%),
haemodialysis (n=11; 4.6%), permanent urinary tube (n=10;
4.2%), gastrostomy (n=9; 3.8%), nasogastric tube (n=4; 1.7%),
permanent catheter (n=2; 0.8%) and close contact with MDR
infection (n=1; 0.4%).
Most patients were hospitalised in pulmonology departments
(HCAP: 77.3%; CAP: 84.5%), while fewer patients were hospi-
talised in internal medicine departments (HCAP: 17.6%; CAP:
11.8%) or other services (HCAP: 8.9%; CAP: 6.3%).
The main patients’ characteristics are shown in table 1. The
two groups did not differ in vaccination rates (flu and pneumo-
coccal), smoking and alcohol history, chronic use of steroids
(both inhaled and systemic) or in the percentage of previous
pneumonia. By contrast, HCAP patients showed a more fre-
quent use of pump inhibitors and of antibiotics in the last
month before pneumonia (table 1). The most frequent antibio-
tics previously administered were: fluoroquinolones in both
groups (HCAP: 29 (44%) vs CAP: 11 (41%); NS), β-lactams
(HCAP: 20 (30.3%) vs CAP: 8 (29.6%); NS) and macrolides
(HCAP: 1 (1.5%) vs CAP: 3 (11.1%); NS).
The median number of comorbidities was clearly higher in
HCAP due to the higher rate of neurological disorders in con-
trast with other diseases (respiratory, cardiac, diabetes, etc) that
showed similar distribution between groups (table 2).
Concordantly, in HCAP dysphagia was more frequent while
body mass index decreased in comparison with CAP.
Among the respiratory diseases, chronic obstructive pulmon-
ary disease (COPD) was the most frequent in both groups, fol-
lowed by bronchiectasis and asthma. As a consequence, patients
with a high severity score (PSI classes IV–V 85% in HCAP vs
68% in CAP; p=0.000) were more frequent in the HCAP group
than in CAP indicating an increased mortality risk (see figure E1
in supplementary data, available online only).
HCAP patients had a higher mean Charlson score for
comorbidities (cases: 2.47, 95% CI 2.25 to 2.69 vs controls:
1.67, 95% CI 1.47 to 1.86; p=0.000) and lower Barthel index
for autonomy (cases: 57.9 points, 95% CI 53.1 to 62.8 vs con-
trols: 83.7, 95% CI 80.2 to 87.3; p=0.000) than CAP (figure 1),
indicating a poorer performance status.
Signs (radiological extension, oxygenation, etc) and symptoms
(fever, dyspnoea, etc) of presentation were similar for both
groups, with the only exception of hypothermia, altered mental
status (both more frequent among HCAP) and chills (less fre-
quent in HCAP) (table 3).
Despite higher initial PSI, HCAP patients showed similar rates
of pulmonary complications (pleural effusion, etc), ICU admis-
sion and MV (cases, 3% vs controls, 2%; p=NS) but a trend
towards more extrapulmonary complications (septic shock, etc)
globally than CAP (table 3).
The HCAP subgroups of ‘nursing home’ (NH) and of ‘recent
hospitalization’ (RH) showed a trend towards an increased inci-
dence of respiratory diseases (COPD, NH: 67%; RH: 57%;
HCAP: 30%) and of both inhaled (NH: 68%; RH: 67%;
HCAP: 21%) and systemic steroids (NH: 32%; RH: 33%;
HCAP: 9%).
Microbiological findings
Most patients underwent a broad microbiological investigation
(see table E4 in supplementary data, available online only), with
at least one positive microbiological result in 83 cases (34.9%)
and 72 controls (30.3%) but two or three different
Table 2 Patients’ characteristics at presentation
Cases (HCAP) Controls (CAP) p Value
BMI, media±SD 25.6 4.3 26.8 4.8 0.029
Comorbidities ≥2, n (%) 158 75% 102 53% 0.000
Respiratory disease, n (%) 118 50% 111 48% NS
COPD 72 30% 61 26% NS
Bronchiectasis 12 5% 6 2.5% NS
Asthma 9 4% 3 1.2% NS
Diabetes mellitus 57 27% 55 28% NS
Cardiac failure 94 45% 99 51% NS
Neurological diseases, n (%) 114 54% 46 24% 0.000
Dysphagia (1–4), n (%) 90 39% 33 14% 0.000
PSI, mean (SD) 123 33 104 29 0.000
PSI I–III, n (%) 35 15% 75 33% 0.000
PSI IV–V, n (%) 198 85% 156 68%
BMI, body mass index; CAP, community-acquired pneumonia; COPD, chronic
obstructive pulmonary disease; HCAP, healthcare-associated pneumonia; PSI,
pneumonia severity index.
Table 1 Patients’ main characteristics
Cases (HCAP)
Controls
(CAP)
p ValueN n=238 n=238
Men, % 68 68
Age, mean±SD (years) 78.8±10.8 77.7±10.1 NS
Current smokers, n (%) 21 8.8% 25 10.5% NS
Ex-smokers, n (%) 102 42.9% 100 42.0%
Alcohol intake >80 g/day, n (%) 3 1% 7 3% NS
Flu vaccine, n (%) 143 63% 152 68% NS
Pneumococcal vaccine, n (%) 41 18% 30 13% NS
Previous pneumonia, n (%) 73 32% 68 29% NS
Previous antibiotic therapy
(last month)
78 33% 34 15% 0.000
Inhaled cortisteroids, n (%) 51 21% 48 20% NS
Systemic steroids, n (%) 21 9% 18 8% NS
Statins 52 22% 49 21% NS
Proton-pump inhibitors, n (%) 124 52% 105 44% 0.048
Anti-H2 drugs 25 17% 8 7.1% 0.017
CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia.
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microorganisms were found contemporarily in 11 cases (10.7%)
and in 10 controls (10.9%) (p=0.200).
S pneumoniae was the most frequent isolated pathogen (63%
vs 71%) followed by respiratory viruses (27% vs 15%),
L pneumophila (5% vs 11%) Gram-negative bacilli (including
Escherichia coli, Klebsiella pneumoniae, Acinetobacter lwoffii,
Proteus mirabilis) (7% vs 6%), P aeruginosa (5% vs 1%),
methicillin-sensitive S aureus (2% vs 3%) and atypical pathogens
(including Mycoplasma pneumoniae, Coxiella burnetii and
Chlamydia pneumoniae) (2% vs 4%). All isolated pathogens
were similarly distributed between cases and controls but
respiratory viruses showed a trend towards increased frequency
among cases while L pneumophila and other atypical pathogens
showed a trend to be more frequent among controls. We did
not observe any specific predominance among the different
respiratory viruses identified in both groups (see table E5 in sup-
plementary data, available online only). Among potential MDR
pathogens P aeruginosa showed only a mild non-significant
trend towards a higher prevalence among cases with
Gram-negative bacilli (table 4). The other Gram-negative iso-
lates corresponded to five cases (one extended-spectrum beta-
lactamase (ESBL) resistant E coli, two non-MDR E coli, one
non-MDR A lwoffii, one non-MDR P mirabilis) and four con-
trols (one ESBL-resistant E coli, three non-MDR E coli).
Figure 1 Patients’ distribution
according to modified Charlson and
Barthel indexes.
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The nasopharyngeal swab identified 16 cases of MRSA (13%
of all isolates) among HCAP and seven among CAP (6%). A
mixed infection was detected in 11% of the total population
(n= 21), corresponding to 11 cases (11% of cases with aeti-
ology) and 10 controls (11% of controls) with a combination of
two different micro-organisms (five cases and five controls with
two different bacteria, two cases and four controls with a bac-
teria plus a virus, one case and one control with two viruses)
and only three cases of three different pathogens (a bacteria
plus two viruses in two cases, and three bacteria in one case)
(see table E6 in supplementary data, available online only).
Most patients (n=424; 92%) received an antibiotic coverage
consistent with Spanish CAP guidelines, with a mild not signifi-
cant trend towards greater adherence for CAP (antibiotic
adequacy: HCAP, 89.6%; CAP 94.3%; p=0.085). Only 11% of
the cases of pneumonia who did not receive recommended anti-
biotic therapy were caused by specific antibiotic allergies, while
5% of the cases were modified according to microbiological
results.
Clinical course and outcomes
The clinical outcomes of HCAP were clearly poorer than for
CAP as both mean LOS (9±SD 8 days vs 7±6 days, p=0.008)
and time to clinical stability (5.7±SD 4.6 days vs 4.8±3.6 days,
p=0.030) were worse for HCAP, as were the rates of 30-day
treatment failure (HCAP, 11cases (5.5%) vs CAP, three cases
(1.5%); p=0.031) and of 30-day readmissions (HCAP, n=37
(18%) vs CAP, n=22 (11%); p=0.030), the majority being for a
respiratory cause (51% among HCAP, 55% among CAP). The
rate of readmissions remained higher for HCAP than for CAP
during the entire study follow-up period (3 months, 22% vs
14%, p=0.054; 12 months, 43% vs 21%, p=0.000), with a
clear prevalence of respiratory causes (59–65%).
The mortality rate was also increased for HCAP patients at
both 1-month (HCAP, n=29 (12.2%) vs CAP, n=11 (4.6%);
p=0.005) and 12-month follow-up (HCAP, n=58 (24.4%) vs
CAP, n=22 (9.2%); p<0.001).
Among patients who died during the study four cases (14%)
and three controls (27%) were admitted to ICU, while six cases
received MV (21%; three non-invasive MV, three invasive MV)
and six controls (55%; four non-invasive MV, two invasive MV).
We analysed mortality rates across aetiological subgroups and
we could only find higher 1-year mortality for S pneumoniae
infection (HCAP, 10 (19.2%) vs CAP, one (2%); p=0.008) and a
slight non-significant trend towards increased 1-year mortality
for respiratory viruses (HCAP, six (27.3%) vs CAP, two (18.2%),
p=0.68) among HCAP. Other aetiologies showed only very few
fatality cases and did not show any statistical differences.
While LOS, readmission and 1-month mortality rates from
NH and RH subgroups were similar to the whole HCAP popu-
lation, treatment failure (12.9% vs 5.5%) and the 1-year mortal-
ity rate (27% vs 24%) showed an increasing trend in the RH
group.
Predictors of mortality
The multivariate analysis identified the following risk factors for
30-day mortality: a chronic cardiac disease (OR 9.95, 95% CI
2.84 to 34.94; p=<0.01), an increased LOS (OR 1.10) and a
decreased autonomy at Barthel score (OR 0.97), a respiratory
rate greater than 30 breaths per min (OR 1.16). Only the pres-
ence of an ‘alveolar’ pulmonary infiltrate at chest X-ray was a
protective factor in comparison with a different pattern (intersti-
tial or mixed pattern) (OR 0.16) (see table E7 in supplementary
data, available online only).
The risk factors associated with 1-year mortality were: HCAP
(OR 3.15), increasing age (+5 years, OR 1.29), prolonged ICU
stay (+1 day, OR 1.26), increased respiration rate (>30 per
Table 4 Microbiological aetiology of pneumonia among patients
with known aetiology
Cases
(HCAP)
Controls
(CAP)
p ValueN % N %
Streptococcus pneumoniae 52 62.7 51 70.8 0.282
Respiratory Viruses 22 26.5 11 15.3 0.116
Legionella pneumophila 4 4.8 8 11.1 0.227
Gram-negative bacilli* 5 7.2 4 5.6 1.000
Pseudomonas aeruginosa 4 4.8 1 1.4 0.373
MSSA† 2 2.4 2 2.8 1.000
Atypical pathogens 2 2.4 3 4.2 0.664
Haemophilus influenza 1 1.2 1 1.4 1.000
Moraxella catarrhalis 1 1.2 0 .0 1.000
Total number 83 72
*Gram-negative bacilli include: Escherichia coli, Klebsiella pneumoniae, Acinetobacter
lwoffii, Proteus mirabilis. Only two of them were multidrug resistant (one case and
one control of ESBL-resistant E coli).
†Methicillin-sensitive Staphylococcus aureus.
CAP, community-acquired pneumonia; ESBL, extended-spectrum beta-lactamase;
HCAP, healthcare-associated pneumonia; Respiratory viruses include: respiratory
syncytial virus, rhinovirus, adenovirus, influenza virus A and B, parainfluenza virus I–
IV, metapneumovirus A and B, enterovirus; Atypical pathogens include: Mycoplasma
pneumoniae, Chlamydia pneumophila, Coxiella burnetii.
Table 3 Clinical presentation of HCAP and CAP patients
Cases
(HCAP)
Controls
(CAP) p Value
Fever, n (%) 161 68 168 71 NS
Hypothermia, n (%) 16 7 4 2 0.005
Chills, n (%) 66 28 92 39 0.016
Cough, n (%) 161 68 176 74 NS
Purulent phlegm, n (%) 67 51 73 51 NS
Digestive symptoms, n (%) 38 16 25 11 NS
Dyspnoea, n (%) 168 71 155 65 NS
Altered mental status, n (%) 63 27 34 14 0.001
PaO2 <65 mm Hg 146 72 122 66 NS
Bacteraemia 24 10.1 19 8.0 NS
Multilobar infiltration, n (%) 57 24 47 20 NS
ICU admission, n (%) 10 4 11 5 NS
NIV, n (%) 10 4 12 5 NS
MV, n (%) 7 3 5 2 NS
Respiratory complications 37 15.5 38 16.0 NS
Distress 7 2.9 7 18.4 NS
Empyema 2 0.8 4 10.5 NS
Pleural effusion, n (%) 26 10.9 26 68.4 NS
Cavitation 2 0.8 1 2.6 NS
Non-respiratory complications 92 38.6 62 26 0.005
Renal failure 33 13.8 20 8.4 NS
Septic shock 11 4.6 6 2.5 NS
Arrhythmia 11 4.6 7 2.9 1.00
Diarrhoea 9 3.8 6 2.5 0.785
Others 28 11.8 23 9.7 0.72
CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia;
ICU, intensive care unit; MV, mechanical ventilation; NIV, non-invasive ventilation;
PaO2, arterial oxygen tension.
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min; OR 2.16). Only the presence of pleuritic pain was a pro-
tective factor (OR 0.40) (see table E8 in supplementary data,
available online only).
We also adjusted the mortality rates for multivariate analysis
for all relevant comorbidities (heart failure, neurological, dia-
betes, chronic respiratory disease, liver and renal diseases) to
assess their role but no one of them individually achieved the
statistical significance to enter the multivariate analysis.
Nevertheless, the HCAP definition was associated with a
twofold increased risk of mortality (OR 2.2, 95% CI 1.21 to
4.07; p=0.010). On the other hand, the Barthel index for
autonomy was a protective factor for mortality (OR 0.99, 95%
CI 0.98 to 0.99; p<0.01).
DISCUSSION
The main findings of this study are:
1. HCAP patients showed worse functional status than CAP
patients despite similar age and clinical presentation.
2. Concordantly to initial PSI, HCAP clinical outcomes were
clearly worse than for CAP; a low Barthel score was asso-
ciated with increased 1-month mortality.
3. The microbiological investigation showed similar patterns in
both groups indicating that microbial aetiology is not the
leading cause of increased mortality from HCAP in Spain.
HCAP patients clearly differ from CAP patients despite
similar age and gender due to the poorer functional status, as
reflected by the number of comorbidities and level of autonomy
for daily activities. In particular, HCAP patients showed a
higher frequency of neurological disorders and dysphagia
(although no anaerobic pathogens were found), particularly
among NH patients. Moreover, a higher proportion of HCAP
patients had recently received antibiotics before an episode of
pneumonia and chronically use gastric acidity inhibitors, a
recognised risk factor for pneumonia.32–34 NH and RH sub-
groups showed an increased frequency of COPD and, in paral-
lel, of steroid use (both systemic and inhaled), a recognised risk
factor for pneumonia.
The clinical presentation was very similar between the two
study groups with the only exception being hypothermia, which
was more frequent among HCAP, and chills, which was more
frequent among CAP, indicating globally that a clinical distinc-
tion between the two groups is almost impossible at medical
examination. Nevertheless, the PSI score was in general higher
for HCAP patients, reflecting the relevant weight of comorbid-
ities on initial pneumonia severity. Interestingly, the rate of
septic shock of HCAP patients was slightly higher than the rate
of ICU suggesting indirectly some treatment restriction for these
patients. In general, a trend towards limited ICU admission and
MV use was observed among HCAP patients, possibly reflecting
a tendency towards a limited use of life-supporting measures or
poorer patient conditions.
The main clinical outcomes clearly reflected the PSI estima-
tion because HCAP showed increased mortality in both the
short and long term, such as worse LOS, readmissions, etc.
The multivariate analyses showed that HCAP is more clearly
associated with long-term mortality (1 year) rather than with
short term (1 month), suggesting a predominant role of poor
functional status on main outcomes. As a confirmation, the
Barthel score for functional status is more strictly correlated
with mortality (multivariate analysis) than comorbidities glo-
bally (Charlson) and individually, suggesting that a low Barthel
score should indicate a more careful patient follow-up after dis-
charge. Indeed, different authors have already described the
prognostic relevance of a functional status assessment for mor-
tality in CAP patients and, possibly, a simple assessment for
mobility autonomy could help in follow-up decisions.35 36
Finally, the microbiological investigation demonstrated that
despite the increased severity at admission and the higher use of
antibiotics before the pneumonia episode, a known risk factor
for MDR infection, HCAP patients showed an aetiological
pattern not far from the typical CAP microbiology.
Nevertheless, a few interesting findings were observed: the
role of viral infections is relevant among HCAP and is probably
also related to bacterial entrance;37 nonetheless, it is worth
remembering that the PCR technique detects genetic material
instead of live microbes; the rates of Gram-negative bacilli and
P aeruginosa infections were similar between HCAP and CAP,
discrediting the hypothesis of a ‘nosocomial microbiological’
pattern for HCAP in Spain and justifying the general Spanish
trend to follow CAP guidelines for antibiotic treatment. Indeed,
the choice of modified criteria for HCAP definition for this
study was taken to ensure a wider selection of potential MDR
risky conditions (by reducing the time since previous hospitalisa-
tion to 2 months and by adding other potential sources of MDR
infections currently and surprisingly not considered by guide-
lines). Nevertheless, few cases of MDR infections were detected
among both HCAP and CAP groups, suggesting that specific risk
factors for MDR infections should be systematically investigated
in the future to improve the antibiotic coverage and possibly
reduce the related excess mortality. Shorr et al24 described an
association between potential MDR pathogens and specific risk
factors (ICU, etc). Indeed, in our series the few HCAP and CAP
cases of potential MDR pathogens made this correlation
with MDR risk factors not evaluable.24 A lower frequency of
L pneumophila was observed among HCAP possibly due to the
limited mobility and reduced contagious risk of these patients.
Another important aspect of the study is the relatively high
proportion of oral colonisation by MRSA, especially among
HCAP (HCAP 16%, CAP 6%), that in association with the
increased risk of broncho-aspiration, could create the alert of
MRSA pneumonia in already compromised patients.
Unfortunately, due to the bad clinical conditions of the main
patients it was possible to perform only a minimal number of
TBAS and bronchoalveolar lavage that would have considerably
increased the rate of microbiological diagnosis and investigated
the role of oral ‘colonisers’ in causing pneumonia through the
aspiration of oropharyngeal secretions. Moreover, the percent-
age of microbiological findings is relatively low despite the
investigators’ efforts, due to the limited ability of many patients
to expectorate.
By contrast, the main strengths of the study are: this is the
first prospective multicentre case–control study conducted in
Europe on an HCAP population; a wide microbiological investi-
gation was systematically performed in all centres using identical
methods; we systematically recorded patients’ functional status
and the long-term clinical outcomes (1 year).
We can therefore conclude that HCAP, according to the ATS/
IDSA definition, clearly corresponds to patients with poor func-
tional status and with multiple comorbidities, who despite
having a similar clinical presentation and similar microbial aeti-
ology show worse clinical outcomes in both the short and long
term. These findings perfectly match with other recent
European studies (UK, Germany, Spain) and corroborate the
idea that the usual CAP antibiotic coverage is still indicated in
these patients in Europe.19 22 38 Moreover, patients with HCAP
criteria possibly deserve more attention during hospitalisation
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regarding poor functional status and comorbidities that could
easily decompensate as a consequence of a respiratory infection;
a more prolonged HCAP follow-up after hospital discharge is
needed due to the higher long-term mortality risk.
However, all our findings do not support the use of HCAP
definition in Spain because the clinical approach to very elderly
or multimorbid patients (follow-up) should not depend on this
classification and the antibiotic choice can still follow CAP
guidelines. Risk factors for potential MDR infections should
always be investigated.
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Polverino E, Torres A, Menendez R, et al. Microbial aetiology of healthcare associated
pneumonia in Spain: a prospective, multicentre, case-control study. Thorax 2013;68:1007–14.
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The date reported under the row ‘Pleural effusion’ in table 3 of this published paper is
incorrect. The correct data for that row is below:
Thorax 2015;70:708. doi:thoraxjnl-2013-203828corr1
Cases (HCAP) Control (CAP) p Value
Pleural effusion, n (%) 26 10,9 26 10,9 NS
708 Liao P-Y, et al. Thorax 2015;70:707–708. doi:10.1136/thoraxjnl-2015-206978
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